PNXP Is Turning Cannabis Logistics Into A Profit Machine

This past year, PINYA XP (OTCID: $PNXP) transitioned beyond its roots as a dispensary brand to become a leading technology platform specializing in cannabis authentication and logistics. This new direction directly confronts a major, ongoing problem: widespread counterfeiting, mislabeling, and compliance failures. These issues exist because there hasn't been a reliable way to verify products. PNXP is now working to close this gap, building a platform for real traceability across the entire supply chain.

The evolution took shape in March when PNXP acquired GROOVY. The GROOVY platform is now part of PNXP's core technology, serving as a blockchain-based system designed for cannabis authentication and supply chain logistics. It establishes real traceability by using QR-NFT tags that link products to immutable digital records on the blockchain, detailing the product's origin, strain data, who handled it, and all its quality control history.

Unlike the manual processes or fragmented third-party tracking common in the cannabis industry, GROOVY offers a seamless, automated solution. Dispensaries can verify inventory upon arrival, and consumers can scan products at the point of sale. Regulators access item-level data for auditing transactions and enforcing compliance. For medical users, confirming contents and dosage in real-time is vital for safety and consistency.

Beyond verification, the platform integrates an AI-powered analytics engine that processes this rich, verified data to generate valuable market insights for cannabis businesses, helping them with forecasting and competitive analysis. It also features a GROOVY Rewards program, allowing consumers to earn rewards redeemable for PNXP meme tokens on Solana and a Geno-NFT Library to offer intellectual property protections on cannabis genetics with automatic royalty distribution for growers. PNXP views this as foundational to building the industry's digital identity and verified inventory infrastructure.

Just yesterday PNXP announced that its Groovy 2.0 platform is currently in a pilot program with Bass River Buds, a licensed New Jersey dispensary selected as its elite beta tester for GROOVY. The beta program, running through Q3, aims to validate the platform for craft cannabis, using its full system for product scans, verified tracking, and consumer rewards. PNXP is refining the platform at this initial location before expanding to more sites. The next phase will include multi-state operators, cultivators, and other dispensaries to drive wider adoption, and using their new UPC tokenization method means complete catalog integration can be completed in minutes.

The North American legal cannabis market offers a significant opportunity for PNXP's solutions, valued at USD 44.83 Billion in 2024 and projected to reach USD 354.82 Billion by 2033, with a CAGR of 24.55%. This expanding market, with its ongoing challenges in supply chain integrity and compliance, creates a vast target for PNXP's platform. PNXP's early entry into this rapidly expanding market positions it to capture significant market share.

PNXP is a bit of a unique player in the cannabis industry and shows clear direction, tackling a genuine industry problem as its core mission. It offers a working product that meets a real need in one of North America's fastest-growing industries. With a market cap just over $200,000 and ~9.4 million unrestricted shares in the float, PNXP has one of the leanest setups seen for a platform this early in its active rollout. As user adoption grows and dispensary partnerships develop, the company is positioned to become a foundational player in the cannabis supply chain, defining the industry's future with its verifiable technology.

---

Disclaimer: Mt. Zion Market Ventures has received compensation for the creation and dissemination of this article. For more information, please visit https://www.opendisclose.com. The information provided here is not intended to be a comprehensive analysis of the subjects mentioned. All information, opinions, and forecasts contained herein should not be construed as investment advice, a recommendation, or an offer to buy or sell any securities or related financial instruments. Investors should conduct their own research or consult with a qualified financial advisor before making any investment decisions. The author and publisher of this content are not responsible for any losses, damages, or other consequences that may result from the use of the information provided. Investing in stocks, including those mentioned here, involves risks, including the risk of loss.